X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs GLENMARK PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA GLENMARK PHARMA GSK PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 60.1 13.9 434.0% View Chart
P/BV x 11.8 3.9 303.8% View Chart
Dividend Yield % 2.1 0.3 638.9%  

Financials

 GSK PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
GLENMARK PHARMA
Mar-16
GSK PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8501,262 305.1%   
Low Rs2,966672 441.6%   
Sales per share (Unadj.) Rs332.3270.6 122.8%  
Earnings per share (Unadj.) Rs44.324.9 178.1%  
Cash flow per share (Unadj.) Rs47.234.4 137.2%  
Dividends per share (Unadj.) Rs50.002.00 2,500.0%  
Dividend yield (eoy) %1.50.2 709.2%  
Book value per share (Unadj.) Rs202.7151.3 134.0%  
Shares outstanding (eoy) m84.70282.16 30.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.33.6 287.0%   
Avg P/E ratio x76.938.9 198.0%  
P/CF ratio (eoy) x72.228.1 256.9%  
Price / Book Value ratio x16.86.4 263.1%  
Dividend payout %112.98.0 1,403.9%   
Avg Mkt Cap Rs m288,643272,778 105.8%   
No. of employees `0004.610.0 46.0%   
Total wages/salary Rs m4,43413,782 32.2%   
Avg. sales/employee Rs Th6,104.57,614.9 80.2%   
Avg. wages/employee Rs Th961.61,374.8 69.9%   
Avg. net profit/employee Rs Th813.7700.2 116.2%   
INCOME DATA
Net Sales Rs m28,14876,340 36.9%  
Other income Rs m1,218356 342.0%   
Total revenues Rs m29,36676,696 38.3%   
Gross profit Rs m4,77414,172 33.7%  
Depreciation Rs m2482,691 9.2%   
Interest Rs m01,789 0.0%   
Profit before tax Rs m5,74410,048 57.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m260-   
Tax Rs m2,0183,028 66.6%   
Profit after tax Rs m3,7527,019 53.5%  
Gross profit margin %17.018.6 91.4%  
Effective tax rate %35.130.1 116.6%   
Net profit margin %13.39.2 145.0%  
BALANCE SHEET DATA
Current assets Rs m21,46259,096 36.3%   
Current liabilities Rs m10,53640,018 26.3%   
Net working cap to sales %38.825.0 155.3%  
Current ratio x2.01.5 137.9%  
Inventory Days Days6875 90.2%  
Debtors Days Days16119 13.8%  
Net fixed assets Rs m4,71739,075 12.1%   
Share capital Rs m847282 300.1%   
"Free" reserves Rs m16,30830,281 53.9%   
Net worth Rs m17,17142,703 40.2%   
Long term debt Rs m1624,873 0.1%   
Total assets Rs m30,620111,026 27.6%  
Interest coverage xNM6.6-  
Debt to equity ratio x00.6 0.2%  
Sales to assets ratio x0.90.7 133.7%   
Return on assets %12.37.9 154.5%  
Return on equity %21.916.4 132.9%  
Return on capital %33.617.5 191.7%  
Exports to sales %043.3 0.0%   
Imports to sales %15.17.4 202.6%   
Exports (fob) Rs m433,044 0.0%   
Imports (cif) Rs m4,2375,672 74.7%   
Fx inflow Rs m51936,945 1.4%   
Fx outflow Rs m8,32061,066 13.6%   
Net fx Rs m-7,801-24,122 32.3%   
CASH FLOW
From Operations Rs m1,3863,449 40.2%  
From Investments Rs m5,010-8,802 -56.9%  
From Financial Activity Rs m-6,3836,986 -91.4%  
Net Cashflow Rs m12934 1.3%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 6.9 147.8%  
FIIs % 23.8 34.4 69.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.5 146.7%  
Shareholders   102,036 56,727 179.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - LUPIN LTD COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS